

PA Health & Wellness Pharmacy and Therapeutics Committee Meeting Minutes 1700 Bent Creek Blvd, Suite 200, Mechanicsburg, PA 17050

Wednesday, July 10, 2024 – 12:00 PM – 1:30 PM

Present:	Jason Skaria, PharmD, Jill Schaeffer, RN, Michelle Bennett, RPh, Dr. Christopher Hughes, Dr. Venkateswara Davuluri, Dr. Craig Butler		
Absent:	Dr. Mahmood Usman, Dr. Kolin Good, Grace Robinson		
Non-Voting Members:	Amy Nowacki (Pharmacy), Rhonda Montesano (Pharmacy), Shalyn Kline (Pharmacy), Evan Sebastian (Pharmacy), Tanayja Sams (Pharmacy), George Kimbrow (Clinical Policy Coodinator), Heather Clarke (Director of Case Management).		
Call to Order:	The PA Health & Wellness Pharmacy and Therapeutics Committee meeting called to order at 12:05 PM.		
Adjourned:	The PA Health & Wellness Pharmacy and Therapeutics Committee meeting was adjourned at 12:12 PM.		
Next Meeting:	Wednesday, October 09, 2024 – 12:00 PM		
Submitted By:	Shalyn Kline (PHW Pharmacy)		
Committee Chair:	Shalyn Kline, PharmD Date: 10/9/2024		

CONFIDENTIAL

Notice: This document comprises the confidential investigations, proceedings, and/or records of a medical review Committee and is not subject to discovery or introduction into evidence in any civil or administrative action. This document contains information deemed confidential by the health care quality improvement act of 1986 (42 U.S.C.S.\(\xi\)1137 (b)).



Agenda Item	Discussion/Recommendation	Action	Next Steps	Owner
I. Introduction & Call to Order	Evan called the PA Health & Wellness Pharmacy & Therapeutics Committee meeting to order at 12:05 PM.	Meeting Called to Order		Jason Skaria
A. Introductions	State name of new member and title or state OR No new introductions			Jason Skaria
B. Announcements	Jason reminded all that 75% attendance is required for all voting members to remain as active committee members. Every month, a report is sent to the state. The state provides feedback, and the necessary follow-up is completed.	No action required or taken.		Jason Skaria
C. Explanation of the Review and Approval Process	i. Voting and vote totalsii. Tie breakeriii. Pennsylvania's Review and Approval Process	No action required or taken.		Jason Skaria
D. Charter Review	The committee charter was reviewed with the committee members.	No action required or taken.		Jason Skaria
II. Approval of Meeting Minutes	A vote was taken for the approval of the minutes from Q2_2024. No objections were made. Motion to approve: Dr. Christopher Hughes Second motion to approve: Jill Schaeffer, RN	Adoption of Q2_2024 Meeting Minutes recorded as approved		Evan Sebastian
III. Old Business	No old business	No action required or taken.		Evan Sebastian

CONFIDENTIAL

Notice: This document comprises the confidential investigations, proceedings, and/or records of a medical review Committee and is not subject to discovery or introduction into evidence in any civil or administrative action. This document contains information deemed confidential by the health care quality improvement act of 1986 (42 U.S.C.S.\(\xi\)1137 (b)).



			& WELLITESS
A. Policy Submission Status	There are 10 outstanding clinical policies awaiting approval.	No action required or taken.	Evan Sebastian
IV. New Business			
A. Statewide PDL updates	According to the CHC contract, a compliance rate of 95 percent is expected. The compliance rate is currently being audited internally. The Pennsylvania Department of Human Services is conducting an audit of prior authorization determination data.		Jason Skaria
B. Provider Education	A vote was taken for the approval of the Emerging Migraine Treatments provider education. No objections were made. Motion to approve: Dr. Christopher Hughes Second motion to approve: Jill Schaeffer, RN	The provider education was Committee approved.	Evan Sebastian
C. FDA Updates	This is informational only and addresses recalls, new drugs, etc. No vote necessary.	Informational	Evan Sebastian
D. Guidelines – Drug Coverage Criteria	Review on Combined Summary Table for summary of revisions. A vote was taken for the approval of 10 new policies created, 17 policies had clinically significant change, 55 policies with no significant changes and 1 policies being replaced/retired for Medicaid. No objections, concerns or comments were made. Motion to approve: Dr. Christopher Hughes	The policy revisions were Committee approved.	Evan Sebastian
E. Additional Drug Lists and Policies and Procedures	Second motion to approve: Jill Schaeffer, RN A vote was taken for the approval of the Supplemental Drug List, Specialty Drug List and 13 Pharmacy Policy & Procedures Motion to approve: Dr. Christopher Hughes Second motion to approve: Jill Schaeffer, RN	The policy and drug lists revisions were Committee approved.	Evan Sebastian

CONFIDENTIAL Notice: This document comprises the confidential investigations, proceedings, and/or records of a medical review Committee and is not subject to discovery or introduction into evidence in any civil or administrative action. This document contains information deemed confidential by the health care quality improvement act of 1986 (42 U.S.C.S.ξ1137 (b)).



			& wellness
F. Highlights of New Medications/ Significant		No action required or	
Changes		taken.	
G. Complaints and Grievances Review	Evan stated that we were unable to obtain determinations upheld, overturned, withdrawn during pre-grievance and will report findings in next P&T meeting.	No action required or taken.	Evan Sebastian
H. Drug Utilization Review	Evan presented the drug utilization review, noted the numbers are for April-May and involve several outreach categories (Adherence, Drug-Drug Interactions, Duplicative Therapy, Excessive Use, High-Risk Medication, Inappropriate Dose, Inappropriate Duration of Therapy, Lack of Therapy) A total of 3327 DUR outreaches were made and 515 resolutions (13% resolved). April-June FWA – There were 91 Participants reviewed with 90 Morphine Milligram Equivalent (MME) or more. 14 participants identified for provider outreach. 19 Participants were identified with three or more practices/hospitals prescribing opioids.	No action required or taken.	Evan Sebastian
I. PBM Oversight	Prior Authorization Audits: • April – 97.17% passed • May – 93.20% passed • June – 95.24% passed Call Center: • April – 772 calls → 99.87% within TAT • May – 717 calls → 99.87% within TAT	No action required or taken.	Jason Skaria
J. Drug Price Disputes	Jason presented drug price disputes for Q2. There where a total of 0 first-level claims. There were also 0 second-level disputes.	No action required or taken.	Jason Skaria

CONFIDENTIAL Notice: This document comprises the confidential investigations, proceedings, and/or records of a medical review Committee and is not subject to discovery or introduction into evidence in any civil or administrative action. This document contains information deemed confidential by the health care quality improvement act of 1986 (42 U.S.C.S.ξ1137 (b)).



			Of an office of
K. Open Forum		No action	Jason Skaria
		required or	
		taken.	
Adjournment	The meeting was adjourned at 12:12 pm	Meeting	Jason Skaria
		adjourned	
	Jason asked for a motion to adjourn.		
	Motion to adjourn: Dr. Christopher Hughes		
	Second motion to adjourn: Jill Schaeffer, RN		

CONFIDENTIAL

Notice: This document comprises the confidential investigations, proceedings, and/or records of a medical review Committee and is not subject to discovery or introduction into evidence in any civil or administrative action. This document contains information deemed confidential by the health care quality improvement act of 1986 (42 U.S.C.S.\(\xi\)1137 (b)).